Randomized, Double-Blind, Crossover, Comparator Pilot Study of DFN-11 Injection (Strength A vs. Strength B) for Rapidly Escalating Migraine

Trial Profile

Randomized, Double-Blind, Crossover, Comparator Pilot Study of DFN-11 Injection (Strength A vs. Strength B) for Rapidly Escalating Migraine

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs DFN 11 (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Dr Reddys Laboratories
  • Most Recent Events

    • 11 Jun 2017 Primary endpoint (The proportion of subjects reporting Pain freedom at 60 minutes post-treatment according to the subject eDiary entries) has not been met as per the results presented at the 59th Annual Scientific Meeting of the American Headache Society.
    • 11 Jun 2017 Results presented at the 59th Annual Scientific Meeting of the American Headache Society
    • 07 Jun 2017 According to a Promius Pharma media release data from this study will be presented at the 59th Annual Scientific Meeting of the American Headache Society (AHS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top